## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 4.0% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (25% of avg), momentum weakening (-5.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($62.34)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Exchange Traded Concepts LLC Sells 15,265 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR**
- Source: MarketBeat | 20251228T090948 | Somewhat-Bullish | Relevance: 100%
- Exchange Traded Concepts LLC reduced its stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by 33.0% in the third quarter, selling 15,265 shares. Institutional investors and hedge funds have shown mixed activity, with several increasing their positions in the biotechnology company. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $61.89, while company insiders have been significant sellers.

**2. Texas Permanent School Fund Corp Buys Shares of 19,104 Arrowhead Pharmaceuticals, Inc. $ARWR**
- Source: MarketBeat | 20251227T100914 | Somewhat-Bullish | Relevance: 100%
- Texas Permanent School Fund Corp recently acquired 19,104 shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), valued at approximately $302,000, marking a new position for the institutional investor. This purchase contributes to a total institutional ownership of about 62.61% for the company, despite recent insider selling. Analysts maintain a "Moderate Buy" rating for ARWR, with an average price target of $61.89, and some firms raising their targets significantly.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Piper Sandler | $100 | $70 | +43% |
| 2025-12-11 | RBC Capital | $80 | $52 | +54% |
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Piper Sandler | main | Overweight |
| 2025-12-11 | RBC Capital | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-12-02 | HC Wainwright & | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 5 ($3.67M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.3% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.7M in recent transactions.
3. Elevated short interest (9.8%): bears positioning against stock.

### Catalysts

- Analyst target momentum: 5 raises (avg +36%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -31% YoY, concerning. Analyst sentiment positive (5 raises, avg +36%). Insider selling cluster ($3.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.6B |
| Beta | 1.29 |
| 52W Range | $9.57 - $72.36 |
| Short Interest | 9.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 9.3% to 4.0% (-5.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 0.0pp (needs >4.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. AM_20 at 4.4% shows strong absolute momentum above own 20MA. Outperforming sector by 3.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.62), momentum weakening. Volume at 25% of 20MA suggests lack of conviction. OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.98% (CS: 91) | Neutral |
| RSI_14 | 68.3 | Neutral |
| MACD Histogram | -0.62 | Bearish |
| vs SMA20 | 1.044x | Above |
| vs SMA50 | 1.357x | Above |
| vs SMA200 | 2.543x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $69.62
- **Stop Loss:** $62.34 (10.5% risk)
- **Target:** $76.90 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 189
- **Position Value:** $13,158.18
- **Portfolio %:** 13.16%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.15x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite and defensive rotation. VIX at 14.2 (2nd percentile) signals low volatility, while positive yield curve (+58bps) and stable economic indicators support continued expansion. Market breadth at 58.7% shows decent participation, but rotation into defensive names and Fed liquidity concerns warrant measured positioning.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*